The anti-neprilysin market is primarily engaged in developing medicines that inhibit neprilysin, a zinc-dependent membrane-bound metalloprotease enzyme. Anti-neprilysin drugs play a vital role in the management of cardiovascular conditions by degrading natriuretic peptides that regulate blood pressure and sodium balance. The drugs have shown clinical benefits in reducing cardiovascular mortality and hospitalization for heart failure when used in combination with angiotensin receptor blockers.

The global anti-neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The increasing prevalence of cardiovascular diseases including hypertension and heart failure presents a major market opportunity for anti-neprilysin drugs. As per the World Health Organization, cardiovascular diseases are the leading cause of death globally, taking an estimated 17.9 million lives each year. Hypertension also affects over 1.13 billion people worldwide. The anti-neprilysin drugs, particularly their combination with other cardiovascular medicines, have demonstrated significant clinical benefits in reducing risks associated with hypertension and heart failure. With rising healthcare expenditure on cardiovascular conditions, the demand for advanced treatment options such as anti-neprilysin medicines is expected to increase remarkably over the forecast period.

Porter's Analysis
Threat of new entrants: The threat of new entrants in the Anti-Neprilysin market is moderate due to the presence of established market leaders and high research and development costs associated with developing new drugs.

Bargaining power of buyers: The bargaining power of buyers is high as there are several companies offering products for heart failure treatment. Buyers can choose from multiple substitute treatment options.

Bargaining power of suppliers: The bargaining power of suppliers is moderate since raw material suppliers have the threat of forward integration by pharmaceutical companies.

Threat of new substitutes: The threat of new substitutes is high due to availability of alternative therapies for heart failure treatment like angiotensin converting enzyme inhibitors.

Competitive rivalry: The competitive rivalry in the market is high due to presence of many global and local players offering generic versions of drugs.

SWOT Analysis

Strengths: Availability of patent-protected brand drugs, rising prevalence of heart failure, strong product pipelines.

Weaknesses: High R&D costs, pricing pressures, dependency on few market leaders.

Opportunities: Growth in emerging markets, new indications, collaborations and partnerships.

Threats: Patent expiries of blockbuster drugs, regulatory pressures, reimbursement issues.

Key Takeaways
The global Anti-Neprilysin market is expected to witness high growth over the forecast period of 2023-2030. The market size for 2024 is estimated at US$ 1,263.3 Mn and is projected to grow at a CAGR of 4.6% during the forecast period.

Regional analysis indicates that North America holds the highest share currently owing to developed healthcare infrastructure and high awareness levels regarding heart failure treatment options. Europe follows next due to increasing focus on innovative drug research. Asia Pacific region is expected to grow at the fastest rate during the forecast period attributed to rising medical expenditures, growing incidences of cardiovascular diseases, and improving access to healthcare in emerging countries like China and India.

Key players operating in the Anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. BIOPROJET holds the leading position and is investing heavily towards research & development and marketing of branded drugs. Novartis AG follows with a diverse product portfolio and global sales network. Regional players especially in Asia are focusing on generic versions to target the price-sensitive markets.